Discovery and Development of Oral Small-molecule Direct-acting Antivirals
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 75N93025C00039-0-9999-1
Grant search
Key facts
Disease
EbolaStart & end year
20252026Known Financial Commitments (USD)
$1,999,195Funder
National Institutes of Health (NIH)Principal Investigator
CEO. SEAN EKINSResearch Location
United States of AmericaLead Research Institution
COLLABORATIONS PHARMACEUTICALS, INC.Research Priority Alignment
N/A
Research Category
N/A
Research Subcategory
N/A
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
The objective is to develop an oral treatment for Ebola virus infection in humans.